Montreal Neurological Institute

KalGene gears up to manufacture and test promising Alzheimer’s treatment with NRC, McGill and CIMTEC

KalGene Pharmaceuticals and the National Research Council of Canada (NRC) are proud to announce the signature of an agreement worth over $1M to develop, scale up, and transfer the technology needed to manufacture a promising novel Alzheimer’s treatment in Canada that the parties have been co- developing since 2015.

The treatment, a biologic molecule made up of a peptide that fights Alzheimer’s and an antibody-based carrier molecule designed to shuttle the peptide into the brain, is a custom- engineered therapeutic developed at NRC.

Published: 3Oct2016

New hope for treatment of multiple sclerosis

A new study led by researchers at the Montreal Neurological Institute and Hospital of McGill University and the MUHC, gets closer to identifying the mechanisms responsible for multiple sclerosis and makes headway in the search for better treatments.

Published: 23Oct2015

Addiction: abnormal communication in the brain

Addiction to cigarettes, drugs and other stimulants has been linked in the past to the brain’s frontal lobes, but now there is scientific evidence that indicates where in the frontal cortex addiction takes hold and how.  Addiction could be a result of abnormal communication between two areas of the frontal lobes linked to decision-making.  The discovery will undoubtedly stimulate clinical work on new therapies for millions of people who suffer from addiction.

Published: 29Jan2013